QF
OREX

QVT Financial’s Orexigen Therapeutics, Inc. OREX Stock Holding History

QVT Financial’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-132,273
Closed -$8.6M – 95
2014
Q1 		$8.6M Buy
132,273
+106,406
+411% +$7.2M 0.49% 60
2013
Q4 		$1.46M Buy
+25,867
New +$1.45M 0.09% 73

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial's OREX Position: Q2 2014 in Review

QVT Financial sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2014, closing a stake of 132,273 shares — an estimated $8.6M sold.

QVT Financial first reported a position in OREX in Q4 2013 and held it in 2 quarters. The position peaked at $8.6M in Q1 2014. 129 funds tracked by Wall St. Rank hold OREX as of Q2 2014.

  • QVT Financial reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • QVT Financial sold 132,273 Orexigen Therapeutics, Inc. shares in Q2 2014, an estimated $8.6M.
  • QVT Financial first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 2 quarters.
  • QVT Financial's Orexigen Therapeutics, Inc. position peaked at $8.6M in Q1 2014.
  • 129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2014.

Based on QVT Financial's 13F filing for Q2 2014, filed 14 Aug 2014.